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Abstract 22 
Methicillin-resistant Staphylococcus pseudintermedius (MRSP) has emerged as a highly 23 
drug-resistant small animal veterinary pathogen. Although often isolated from 24 
outpatients in veterinary clinics, there is concern that MRSP follows a veterinary-25 
hospital-associated epidemiology. This study’s objective was to identify risk factors for 26 
MRSP infections in dogs and cats in Germany. Clinical isolates of MRSP cases (n=150) 27 
and methicillin-susceptible S. pseudintermedius (MSSP) controls (n=133) and their 28 
corresponding host signalment and medical data covering the six months prior to 29 
staphylococcal isolation were analyzed by multivariable logistic regression. The identity 30 
of all MRSP isolates was confirmed through demonstration of S. intermedius-group 31 
specific nuc and mecA. In the final model, cats (compared to dogs, OR 18.5, 95%CI 1.8-32 
188.0, P=0.01), animals that had been hospitalised (OR 104.4, 95%CI 21.3-511.6, 33 
P<0.001), or visited veterinary clinics more frequently (>10 visits OR 7.3, 95%CI 1.0-34 
52.6, P=0.049) and those that had received topical ear medication (OR 5.1, 95% CI 1.8-35 
14.9, P=0.003) or glucocorticoids (OR 22.5, 95%CI 7.0-72.6, P<0.001) were at higher 36 
risk of MRSP infection, whereas S. pseudintermedius isolates from ears were more 37 
likely to belong to the MSSP-group (OR 0.09, 95% CI 0.03-0.34, P<0.001). These 38 
results indicate an association of MRSP infection with veterinary clinic/hospital settings 39 
and possibly with chronic skin disease. There was an unexpected lack of association 40 
between MRSP and antimicrobial therapy; this requires further investigation but may 41 
indicate that MRSP is well adapted to canine skin with little need for selective pressure. 42 
 43 
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Introduction 46 
Staphylococcus pseudintermedius, belonging to the Staphylococcus intermedius group 47 
is a frequent opportunistic commensal and the most important staphylococcal pathogen 48 
in dogs and cats and frequently affects the skin, ears and wounds (Devriese et al., 2005; 49 
Holm et al., 2002; White et al., 2005). Until recently, treatment of the great majority of 50 
S. pseudintermedius infections caused few problems in small animal veterinary practice 51 
as a wide range of authorized antimicrobial drugs showed good efficacy both in vitro 52 
and in vivo (Beco et al., 2012; Lloyd et al., 1996; Pellerin et al., 1998; Rantala et al., 53 
2004). However, the emergence of methicillin-resistant S. pseudintermedius (MRSP) 54 
over the past ten years and its continuing spread worldwide (Gortel et al., 1999; Jones et 55 
al., 2007; Morris et al., 2006; Loeffler et al., 2007; Ruscher et al., 2009), present 56 
significant clinical challenges to veterinary surgeons. In addition, MRSP has 57 
implications for public health as it can spread between people and pets via direct and 58 
indirect contact and rarely MRSP infections in humans have been described 59 
(Campagnile et al., 2007; Gerstadt et al., 1999; Stegmann et al., 2010; van Duijkeren et 60 
al., 2011 a & b).  61 
Resistance to methicillin in staphylococci is encoded by the gene mecA which confers 62 
resistance to all β-lactam antibiotics (Chambers, 1997). Epidemiologically, the 63 
significance of mecA-positive staphylococci is greatest in the context of nosocomial 64 
infections. Such isolates are likely to emerge as a consequence of antimicrobial 65 
selection pressure in hospitals and are typically multidrug-resistant. In MRSP, several 66 
other resistance genes have been identified which often render all clinically relevant pet-67 
authorized systemic antimicrobial drugs ineffective (Kadlec and Schwarz, 2012). For 68 
canine pyoderma, it has been shown that most MRSP infections can still be resolved 69 
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with topical antibacterial therapy and/or with the help of more ‘exotic’ or less frequently 70 
used antimicrobials but that treatment may be prolonged and may be more frequently 71 
associated with adverse effects (Bryan et al., 2012; Loeffler et al., 2007). Knowledge of 72 
risk factors that contribute to MRSP infection becomes highly relevant since early 73 
identification of predisposed patients should facilitate implementation of infection 74 
control and prevention strategies.  75 
Risk factors such as antimicrobial therapy, surgical interventions and chronic disease 76 
have been suspected for MRSP infection in pets based on the initially observed clinical 77 
presentations in chronic skin and wound infections in hospitalised animals.. 78 
Antimicrobial therapy during the 30 days prior to sampling was recently identified as a 79 
risk factor for MRSP infection in 56 hospitalised dogs in a North American case-control 80 
study while other medication (topical antibacterial therapy, glucocorticoids), animal 81 
signalment, clinical characteristics and veterinary interventions (such as concurrent 82 
disease, type of infection, surgery, hospitalisation) were not associated with outcome 83 
(Weese et al., 2012). For MRSP carriage in dogs and cats admitted to a veterinary 84 
hospital, previous hospitalisation and antimicrobial therapy in the six months before 85 
sampling have been proposed as risk factors (Nienhoff et al., 2011 a & b). Studies on 86 
risk factors for MRSP infection in cats have not been published to the authors’ 87 
knowledge.  88 
This study aimed to identify risk factors for MRSP infection in dogs and cats in two 89 
regions in Germany with a particular focus on exploring a possible veterinary care-90 
associated epidemiology. 91 
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Materials & Methods 93 
Study groups 94 
Privately owned dogs and cats with S. pseudintermedius infection were eligible for 95 
inclusion in a prospective unmatched 1:1 case-control study. Cases with MRSP 96 
infection and controls with methicillin-susceptible S. pseudintermedius  (MSSP) 97 
infection were identified based on bacterial isolation from clinical samples. Samples had 98 
been submitted for bacterial culture and antimicrobial susceptibility testing to one of 99 
two laboratories in Germany (SynlabVet, Geestacht, Germany and Institute for Hygiene 100 
and Infectious Diseases, Justus-Liebig University, Giessen, Germany). SynlabVet 101 
Laboratory received submissions directly from general veterinary practices in the 102 
surrounding area and from a dermatology referral centre (Tierärztliche Spezialisten, 103 
Hamburg, Germany). The Giessen university laboratory received submissions from 104 
general veterinary practices in the surrounding area as well as samples from 105 
dermatology, surgery and internal medicine referral services within the university 106 
teaching hospital. Samples had been taken by veterinary surgeons as part of their 107 
diagnostic investigations into suspected canine and feline bacterial infection. All MRSP 108 
isolates identified between October 2010 and October 2011 inclusive were considered. 109 
MSSP isolates were selected throughout the study period using simple randomization on 110 
www.randomizer.org. 111 
Enrolment criteria 112 
Animals were enrolled with their S. pseudintermedius isolate if their original bacterial 113 
isolate had been preserved (lyophilised or frozen in tryptone soya broth with 20% 114 
glycerol) by the diagnostic laboratory, when its identity had been confirmed by the 115 
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phenotypic methods described below and when the corresponding questionnaire had 116 
been returned by the submitting veterinary surgeon for analysis; they were excluded if 117 
no or insufficiently completed questionnaires had been returned after two weekly 118 
reminder follow-up phone calls.  119 
Questionnaires 120 
When reporting S. pseudintermedius isolation, the laboratories invited the submitting 121 
veterinary surgeons to participate in the study and to complete a questionnaire. 122 
Questionnaires were returned by the participants via the laboratories to the lead 123 
investigator (GL) by fax, email or post. Cases and controls were coded and pet and 124 
owner details were deleted on receipt by the lead investigator (GL) to ensure 125 
confidentiality. Where the Hamburg dermatology referral centre or a referral service at 126 
Giessen University had submitted samples to the laboratories, copies of the animal’s 127 
referral medical history were used to complete the questionnaire and referring general 128 
practitioners were contacted if this information was incomplete. Data were collected on 129 
each animal’s i) signalment, ii) medical history including clinical presentation, sample 130 
site, previous veterinary consultations (not including the visit at the time of sampling) 131 
and hospitalisation and iii) medication prescribed in the six months prior to S. 132 
pseudintermedius isolation. One course of antibacterial therapy was defined as the same 133 
antibacterial therapy given on consecutive days, while a change of drug or an 134 
interruption of treatment of at least one day constituted different courses.  135 
Microbiological identification of MRSP and MSSP 136 
Initial identification of S. pseudintermedius by the diagnostic laboratories was based on 137 
routine bacteriological methods used for phenotypic identification of S. intermedius-138 
group (SIG) isolates (Barrow and Feltham, 2004). Methods specified for use by both 139 
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laboratories included assessment of colony morphology and haemolysis on sheep blood 140 
agar, the detection of clumping factor by slide coagulation test with rabbit plasma or by 141 
a commercial agglutination test (Pasteurex Staph Plus®, Bio-Rad, Munich, Germany) 142 
and a Voges-Proskauer-reaction. As all SIG isolates had originated from dogs or cats, 143 
they were assumed to represent S. pseudintermedius  (Bannoehr and Guardabassi, 144 
2012). Resistance to methicillin and antimicrobial agents commonly used for therapy in 145 
small animal patients was determined through disc diffusion tests using oxacillin (OX 1 146 
C Mast Diagnostica GmbH, Reinfeld, Germany) on Mueller-Hinton agar (Merck, 147 
Darmstadt, Germany) or with MRSA-Ident-Agar (Heipha, Eppelheim, Germany) and 148 
with VITEK2 (Biomérieux, Nürtingen, Germany). Breakpoints for disc diffusion tests 149 
were according to Din 58940-3, supplement 1 (DIN, 2011).  150 
All S. pseudintermedius isolates were re-grown at the end of the enrolment period and 151 
posted to the Royal Veterinary College on nutrient agar slopes or plates. Phenotypic 152 
tests for initial genus and species identification were repeated from subcultures on 5% 153 
ovine blood agar (Oxoid, Basingstoke, UK) as previously described (Loeffler et al., 154 
2007). The identity of MRSP isolates was confirmed phenotypically after growth on 155 
mannitol salt agar containing 4% oxacillin (MSAox) (Oxoid, Basingstoke, UK) and 156 
genotypically through demonstration of mecA after polymerase chain reaction (Brakstad 157 
et al., 1993). In addition, methicillin-resistant isolates were differentiated genetically 158 
from non-pigmented strains of MRSA by demonstration of the S. intermedius-159 
groupthermonuclease gene, nuc (Becker et al., 2005), and those negative for S. 160 
intermedius-group nuc were tested for S. aureus-specific nuc (Baron et al., 2004). 161 
Data analyses 162 
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Data were collected for 20 variables into Microsoft, Excel for Mac 2011, Version 14.3.0 163 
spread sheets. All descriptive statistical analyses were performed using SPSS 17.0 164 
software for Windows, whereas regression analyses were done using Stata/IC 11.2. 165 
Variables listed in Table 1 were analysed by univariable logistic regression for their 166 
association with MRSP infection. Referral practice origin of all submissions  was also  167 
compared by chi-squared test. Continuous variables were initially categorised (based on 168 
quartiles) to assess the shape of their association with the outcome, using likelihood 169 
ratio tests to assess departure from linear trend where appropriate. Variables with a 170 
likelihood ratio test p-value of <0.20 in univariable analysis were considered for 171 
inclusion in a multivariable model, built using a forward stepwise approach. The model 172 
building process started with variables most strongly associated with the outcome in 173 
univariable analysis, adding exposure variables one by one to assess the presence and 174 
direction of potential confounding. To adjust for potential clustering of cases by origin 175 
of sample submission, origin was included in the multivariable model as a random 176 
effect. This variable was categorised according to samples coming from general 177 
practitioners (Synlab); dermatology referral centre (Synlab); dermatology referral 178 
service (Giessen); internal medicine referral service (Giessen); surgery referral service 179 
(Giessen) and external general practitioners (Giessen).  All variables not included in the 180 
final model were then forced back into the model, one by one, to check for their 181 
statistical significance when adjusted for the other variables in the model. Pair-wise 182 
interactions were tested for between variables included in the final multivariable model.  183 
Reliability of estimates in the random effects model was assessed by checking the 184 
sensitivity of quadrature approximation (quadchk command in Stata). The level of 185 
statistical significance was set at p<0.05.   186 
 187 
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Results  188 
Enrolment  189 
During the study period, 2130 S. pseudintermedius isolates were identified. MRSP 190 
accounted for 11.6% (248/2130) of S. pseudintermedius submissions overall with 10% 191 
(109/1090) isolated at Synlab Vet Hamburg and 13.3% (139/1040) at Giessen university 192 
laboratory. At the latter laboratory, MRSP was more frequent (χ2 40.8, P<0.001) in 193 
submissions from the referral services at the university teaching hospital (87/360, 194 
24.2%) compared with those submitted by non-university veterinary clinics (52/680, 195 
7.7%). 196 
The return rate for questionnaires was 66.1% (164/248) for MRSP infected animals and 197 
80.6% (133/165) for MSSP control animals.  The identities of eleven methicillin-198 
resistant isolates classified as MRSP using phenotypic methods could not be confirmed 199 
genetically (three were identified as MRSA) and three MRSP strains were lost.  In total, 200 
283 animals were enrolled including 150 cases and 133 controls.  201 
Animals 202 
Most S. pseudintermedius infections had been diagnosed in dogs (266/283, 94%) for 203 
both cases and controls (Table 1).  However, of the 17 affected cats, only one was in the 204 
control group. Sex and numbers of different breeds were evenly distributed with 92 205 
(61.3%) males and 58 (38.6%) females amongst the cases and 71 (53.3%) males and 62 206 
(46.6%) females amongst the controls.  Of the dogs with MRSP infection, 133 (88.6%) 207 
were pure-bred (50 different breeds) and 17 (11.3%) were cross breeds.  Of the MSSP 208 
infected dogs, 108 (81.2%) were pure-bred dogs (50 different breeds) and 25 (18.7%) 209 
were cross breeds. The majority of cats (14/17, 82.3%) were domestic short-haired cats. 210 
Cases had a mean age of 6.5 years (range 1-18 years, SD 3.8) and a mean bodyweight of 211 
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24.9 kg (range 3-85, SD 16.2); controls had a mean age of 6.4 years (range 1-16, SD 212 
3.8) with a mean bodyweight of 25.9 kg (range 3-85, SD 15.3).   213 
Clinical characteristics of S. pseudintermedius infection  214 
Of all S. pseudintermedius submissions, 212/283 (74.9%) were from surface sites (skin 215 
and wounds) while other affected organs included the respiratory tract in 25 (8.8%), the 216 
urogenital tract in 25 (8.8%) and miscellaneous organs in 21 patients (7.4%). Surface 217 
sites from which S. pseudintermedius was isolated included pyoderma lesions (35%, 218 
99/283), ear canals (17%, 48/283), claws and claw folds (3.5%, 10/283) and post-219 
surgical wounds (19.4%, 55/283; 38 and 17 from sites of orthopaedic and soft tissue 220 
surgery, respectively). Interestingly, four of the pyoderma lesions had been recorded at 221 
previous intravenous catheter sites with all yielding MSSP. Of the 16 MRSP positive 222 
cats, 71% were hospitalised and 50% had a history of surgery, 70% had non-cutaneous 223 
diseases and in 25% MRSP was isolated from the urogenital tract. MRSP was less often 224 
found in ears (8.7%, 13/150) than MSSP (26.3%, 35/133)(Table 1).  225 
Antibacterial agents had been used systemically in 78.1% (221/283) of animals prior to 226 
sampling and topically (excluding ear drops) in 15.9% (45/283). Overall, 46.9% 227 
(133/283) had received more than one course of systemic antimicrobials in the six 228 
months prior to sampling. Four courses of antimicrobials had been prescribed to 18.6% 229 
(28/150) of MRSP cases and to 6.7% (9/133) of MSSP controls over the same period . 230 
Cephalosporin and fluoroquinolone therapies were both associated with MRSP infection 231 
in the univariable analysis (Table 1). In total, 21.2% (60/283) of animals had received 232 
medicated ear drop preparations in the six months prior to S. pseudintermedius 233 
isolation. 234 
Regression analyses 235 
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Of the 20 variables investigated, 11 (species, number of visits to a veterinary clinic, 236 
admission to hospital, surgery, isolation from wounds, concurrent disease, systemic 237 
antimicrobial therapy, number of antibiotic courses, cephalosporins, fluoroquinolones 238 
and systemic glucocorticoid therapy) significantly increased the odds of MRSP (at 239 
p<0.05) while 4 variables significantly decreased the odds of MRSP (seen at a referral 240 
centre, isolation from a cutaneous site, isolation from ears and pruritus) (Table 1). 241 
The final multivariable model is shown in Table 2. The risk for MRSP infection 242 
compared with MSSP infection was higher in cats than in dogs and in animals that had 243 
been hospitalised, had visited veterinarians more frequently and in those that had 244 
received glucocorticoids. Animals from which S. pseudintermedius had been isolated 245 
from ears were more likely to be in the control group. However, ear drops, when forced 246 
back into the model manually were associated with MRSP isolation.  No interactions 247 
between variables included in the final model were identified and model estimates were 248 
found to be reliable based on the quadrature sensitivity check.   249 
 250 
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Discussion 251 
This study confirms that MRSP should be regarded as a hospital-associated pathogen in 252 
small animal veterinary practice and it provides data that emphasise the need for 253 
rigorous hygiene measures and awareness of MRSP as an important contagion.  254 
The estimates reported here need to be interpreted with caution for categories where 255 
numbers were low, e.g. cats. An additional bias may have been introduced by the higher 256 
questionnaire return rate from control animals. This could be due to concern over 257 
certain clinics becoming associated with multidrug-resistance.  258 
Definitions for nosocomial (healthcare-associated) infection are difficult to extrapolate 259 
to a veterinary environment where pets are often seen as outpatients. However, a 260 
veterinary-care-associated epidemiology will be likely for diseases where an increased 261 
risk of infection is found associated with veterinary interventions or institutions 262 
(Johnson, 2002). The strong association between MRSP infection and hospitalisation, 263 
frequent visits to veterinary practices and likely involvement in patients with chronic 264 
skin disease indicates that MRSP is an opportunistic pathogen thriving in patients that 265 
require repeated veterinary medication or intervention. This supports previous studies 266 
into carriage of MRSP in pets and of infection with other multidrug-resistant 267 
staphylococci (Nienhoff et al., 2011 a & b; Eckholm et al., 2013; Soares-Magalhães et 268 
al., 2010).  269 
An important reason for a veterinary-care-related acquisition of MRSP may be the 270 
opportunity for transmission in veterinary clinics and hospitals via contaminated 271 
environment, vector activity of staff or through other colonised or infected pets. 272 
Contamination of veterinary hospitals with MRSP has been documented for surfaces 273 
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contacted by hospital staff (Bergström et al., 2012) while animal-exposed areas such as 274 
weighing scales have yielded large numbers of SIG isolates previously (Hamilton et al., 275 
2012). Based on the long-term survival ability of staphylococci on environmental 276 
surfaces (Wagenvoort et al., 2000) and the good adherence of S. pseudintermedius to 277 
canine corneocytes (Wooley et al., 2008), the veterinary intervention-associated risk 278 
factors identified in this study can be considered biologically meaningful. 279 
With cats less frequently colonised by S. pseudintermedius, including MRSP (Couto et 280 
al., 2011, Nienhoff et al., 2011b) and less often suffering from staphylococcal 281 
infections, numbers of cats in this study were low (6%, 17/283) as expected. Although 282 
with a large confidence interval, cats showed a substantially increased risk for MRSP 283 
infection though, which may imply that infection in cats is indeed more likely to be of 284 
hospital-or clinic related origin. 285 
Systemic glucocorticoid therapy was shown to predispose to MRSP carriage in dogs in 286 
both the present and in a previous study (Nienhoff et al., 2011a).  Since allergic skin 287 
disease and the associated skin barrier dysfunction is known to favour staphylococcal 288 
infection in dogs, and since allergy is commonly managed with gluocorticoids, it is 289 
perhaps possible that glucocorticoid therapy favoured MRSP indirectly through the 290 
need for repeated antimicrobial therapy and visits to veterinary clinics. 291 
The lack of positive association between MRSP and antimicrobial therapy in the final 292 
model was surprising in view of the more frequent antimicrobial prescription to MRSP 293 
animals found in the univariable analysis.  However, the link between antimicrobial 294 
therapy and MRSP infection has not always been reported consistently. Antimicrobial 295 
drug therapy was the most important risk factor for methicillin-resistance in 296 
staphylococci in dogs with superficial pyoderma (Eckholm et al., 2013) and in a study 297 
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of dogs in referral hospitals in Canada (Weese et al., 2012), antimicrobial therapy was 298 
the only variable associated with MRSP infection, albeit related to the 30 days prior to 299 
sampling. In contrast, a longitudinal study found no association between the 300 
development of MRSP infection and prior antimicrobial therapy (Beck et al., 2012). 301 
Strain-specific variation or the longer time window for antimicrobial therapy in our 302 
study may explain these differences. It is possible that analysis of more recent 303 
antimicrobial therapy might have shown a stronger effect on MRSP selection as 304 
adaption to different niches may occur more rapidly than anticipated. Alternatively, 305 
MRSP may be equally well adapted to canine skin as MSSP with little need for 306 
selective pressure (Beck et al., 2012).  307 
 308 
Another unexpected finding was the association between topical ear medication and 309 
MRSP isolation. It is likely though that some dogs may have had MRSP isolated from 310 
other body sites and received ear drops for otitis associated with a chronic skin disease 311 
such as allergy.  312 
Conclusion 313 
The identification of MRSP in 12% of S. pseudintermedius submissions to veterinary 314 
laboratories and the strong association between MRSP and veterinary institutions 315 
confirm MRSP as an important veterinary care-associated bacterium. In particular, 316 
veterinary surgeons dealing with patients with chronic skin disease and with 317 
hospitalised animals need to be aware as early recognition and implementation of 318 
rigorous hygiene measures are paramount to limit spread and reduce the risk to other 319 
pets and people.  320 
 321 
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Table 1: Univariable analysis of putative risk factor variables from animals with MRSP 461 
infection (cases, n=150) and controls with MSSP infection (n=133).  462 
Variable level MRSP 
n (%) 
MSSP 
n (%) 
OR 95% CI p-value 
Species 
Dog 
Cat 
134 (89.3) 
16 (10.7) 
132 (99.2) 
1 (0.8) 
Ref. 
15.8 2.1-120.6 0.008 
Sex 
Female  
Male 
58 (38.7) 
92 (61.3) 
62 (46.6) 
71 (53.4) 
Ref. 
1.4 0.9-2.2 0.18 
Age in years 
≤ 34 to 6 
7 to 9  
≥ 10 
41 (27.3) 
37 (24.7) 
41 (27.3) 
31 (20.7) 
37 (27.8) 
36 (27.1) 
30 (22.6) 
30 (22.6) 
Ref. 
0.9 
1.2 
0.9 
0.5-1.8 
0.6-2.4 
0.5-1.8 
 
0.82 
0.53 
0.84 
Body weight 
≤ 15 kg 
> 15 kg 
58 (38.8) 
92 (61.3) 
43 (32.3) 
90 (67.7) 
Ref. 
0.8 0.5-1.2 0.27 
Visits to a veterinary institution prior to sampling visit* 
0 
1 to 5 
6 to 10 
> 10 
4 (2.7) 
57 (38.0) 
41 (27.3) 
48 (32.0) 
8 (6.0) 
91 (68.4) 
26 (19.6) 
8 (6.0) 
Ref. 
1.3 
3.2 
12.0 
0.4-4.4 
0.9-11.5 
2.9-49.4 
0.72 
0.08 
0.001 
Seen at referral centre 
No 
Yes 
73 (48.6) 
77 (51.3) 
88 (66.2) 
45 (33.8) 
Ref. 
0.5 0.3-0.8 0.003 
Admission to hospital 
No 
Yes 
76 (50.7) 
74 (49.3) 
131 (98.5) 
2 (1.5) 
Ref. 
63.8 15.2-267.2 <0.001 
Surgery 
No 
Yes 
90 (60.0) 
60 (40.0) 
126 (94.7) 
7 (5.3) 
Ref. 
12.0 
 
5.2-27.5 
 
<0.001 
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Wounds 
No 100 (66.6) 128 (96.2)  Ref. 
Yes 50 (33.3) 5 (3.8) 12.8 4.9-33.3 <0.001 
Isolated from cutaneous site (skin, ears, claw and catheter sites) 
No 
Yes 
85 (56.7) 
65 (43.3) 
41 (30.8) 
92 (69.2) 
Ref. 
0.3 0.2-0.6 <0.001 
Isolated from ears 
No 
Yes 
137 (91.3) 
13 (8.7) 
98 (73.7) 
35 (26.3) 
Ref. 
0.3 0.1-0.5 <0.001 
Concurrent diseases 
No 
Yes 
47 (31.3) 
103 (68.7) 
75 (56.4) 
58 (43.6) 
Ref. 
2.8 1.7-4.6 <0.001 
Pruritus 
No  
Yes 
92 (61.3) 
58 (38.7) 
59 (44.4) 
74 (55.6) 
Ref. 
0.5 0.3-0.8 0.004 
Systemic antimicrobials 
No 
Yes 
18 (12) 
132 (88.0) 
44 (33.1) 
89 (66.9) 
Ref. 
3.6 2.0-6.7 <0.001 
Number of antimicrobial courses 
0 
1 
≥ 2 courses 
18 (12.0) 
45 (30.0) 
87 (58.0) 
44 (33.1) 
43 (32.3) 
46 (34.6) 
Ref. 
2.6 
4.6 
1.3-5.1 
2.4-8.9 
0.008 
<0.001 
Cephalosporins 
No 
Yes 
99 (66.0) 
51 (34.0) 
107 (80.5) 
26 (19.5) 
Ref. 
2.1 1.3-3.7 0.007 
Fluoroquinolones 
No 
Yes 
105 (70.0) 
45 (30.0) 
113 (84.9) 
20 (15.0) 
Ref. 
2.4 1.3-4.3 0.004 
Systemic glucocorticoids 
No 
Yes 
106 (70.7) 
44 (29.3) 
128 (96.2) 
5 (3.8) 
Ref. 
10.6 4.1-27.8 <0.001 
Topical antimicrobials (shampoos, gels) 
No 127 (84.7) 111 (83.5) Ref. 0.5-1.7 0.78 
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Yes 23 (15.3) 22 (16.5) 0.9 
Ear drops 
No 
Yes 
118 (78.7) 
32 (21.3) 
105 (78.9) 
28 (21.1) 
Ref. 
1.0 0.6-1.8 0.95 
Information was based on questionnaire data referring to the six months prior to S. 463 
pseudintermedius isolation. Ref.: reference category; OR: odds ratio; CI: confidence 464 
interval. *Modelled as ordered categories (none, 1-5, 6-10, >10). 465 
 466 
 467 
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Table 2: Final mixed-effects multivariable regression model for putative risk factors for 468 
MRSP infection in dogs and cats.  469 
Variable  Value OR 95% CI Wald test 
p-value 
LRT 
p-value 
 Species Dog  
Cat 
Ref. 
18.5 
 
1.8 – 188.0 
 
0.01 
0.008 
Visits to a veterinary institution                       
prior to sampling visit 
None
1 to 5 
6 to 10 
>10 
Ref. 
1.1 
1.6 
7.3 
 
0.2 – 6.5 
0.2 – 10.7 
1.0 – 52.6 
 
0.94 
0.63 
0.049 
0.004 
Admission to hospital No 
Yes 
Ref. 
104.4 
 
21.3 – 511.6 
 
<0.001 
<0.001 
Isolated from ears No 
Yes 
Ref. 
0.09 
 
0.03 – 0.34 
 
<0.001 
<0.001 
Systemic glucocorticoids No 
Yes 
Ref. 
22.5 
 
7.0 – 72.6 
 
<0.001 
<0.001 
Ear drops No 
Yes 
Ref. 
5.1 
 
1.8 – 14.9 
 
0.003 
0.002 
Sample origin     0.056
†
 
Information was based on 283 questionnaires with data referring to the six months prior 470 
to S. pseudintermedius isolation. Sample origin was included in the model as a random 471 
effect. Ref.: reference category; OR: odds ratio; CI: confidence interval; LRT: 472 
likelihood ratio test. 
†
p-value derived from a test of the null hypothesis that there is no 473 
correlation between samples from the same origin. 474 
